Abstract: The present application provides polynucleotides, compositions thereof and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 (FHV-1) in vivo and/or in vitro.
Type:
Grant
Filed:
February 12, 2009
Date of Patent:
July 12, 2011
Assignee:
University of Tennessee Research Foundation
Abstract: Methods, matrix compositions and kits for increasing the mortality of termites (R. flavipes) and interfering with termite development using RNA interference techniques to target cellulase, lignocellulase, hexamerin, broad, farnesoic acid methyl transferase, cytochrome P450 and vitellogenin activity are provided.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
June 28, 2011
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Michael E. Scharf, Xuguo Zhou, Faith M. Oi, Marsha M. Wheeler, Matthew R. Tarver, Monique R. Coy
Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
June 21, 2011
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
Abstract: The present invention refers to sense and antisense peptide nucleic acids (PNAs). The present invention further refers to the use of said PNAs for preparing drugs for treating genetic diseases.
Type:
Grant
Filed:
April 29, 2004
Date of Patent:
May 24, 2011
Assignees:
Universita Degli Studi Di Parma, Universita Degli Studi Di Bolonga
Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various bacterial infections. Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Type:
Grant
Filed:
April 30, 2010
Date of Patent:
May 17, 2011
Assignee:
Novartis AG
Inventors:
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.
Type:
Grant
Filed:
June 5, 2006
Date of Patent:
May 17, 2011
Assignees:
President and Fellows of Harvard College, Immune Disease Institute, Inc.
Inventors:
Judy Lieberman, Deborah Palliser, David Knipe
Abstract: The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Type:
Grant
Filed:
April 30, 2010
Date of Patent:
May 10, 2011
Assignee:
Novartis AG
Inventors:
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least two siRNAs which silences at least a first target gene. The gene silencing composition can be configured such that the at least two siRNAs are each capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the siRNAs can include a hairpin structure, modification, or a conjugate. Also, the at least siRNAs can be rationally designed. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.
Type:
Grant
Filed:
November 18, 2005
Date of Patent:
April 12, 2011
Assignee:
Dharmacon, Inc.
Inventors:
Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
Abstract: A method of determining a cellular response to a biological agent can be preformed in the presence of gene silencing. Such a method can include the use of siRNA in order to silence various genes in the cell in order to monitor the cellular response to the biological agent when a gene has been silenced. Accordingly, the response of a cell having a silenced gene to a biological agent can be indicative of which genes may be responsible for normal or abnormal cellular responses to various synthetic and natural biological agents such as active agents or pathogens.
Type:
Grant
Filed:
November 18, 2005
Date of Patent:
April 12, 2011
Assignee:
Dharmacon, Inc.
Inventors:
Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
Abstract: Compositions and methods for activating genes of interest are provided. The compositions comprise a masked targeted expression cassette which expresses a gene product only in the presence of a target molecule. The cassettes are useful for the treatment of disease and for preventing the proliferation of neoplastic cells.
Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
Type:
Grant
Filed:
August 25, 2006
Date of Patent:
April 5, 2011
Assignee:
CoDa Therapeutics, Inc.
Inventors:
Richard Colin Green, David Laurence Becker
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
Abstract: The present invention provides methods for synthesis and therapeutic use of DNA and RNA oligonucleotides and analogs. RNA oligonucleotides are synthesized using a small, circular DNA template which lacks an RNA polymerase promoter sequence. The RNA synthesis is performed by combining a circular single-stranded oligonucleotide template with an effective RNA polymerase and at least two types of ribonucleotide triphosphate to form an RNA oligonucleotide multimer comprising multiple copies of the desired RNA oligonucleotide sequence. Preferably, the RNA oligonucleotide multimer is cleaved to produce RNA oligonucleotides having well-defined ends. Preferred RNA oligonucleotide multimers contain ribozymes capable of both cis (autolytic) and trans cleavage.
Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as genomic address messenger or GAM oligonucleotides, and a second group of novel operon-like polynucleotides, here identified as genomic record or GR polynucleotides. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 1708 GAM oligonucleotides, and 246 GR polynucleotides as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotide and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
Type:
Grant
Filed:
August 29, 2006
Date of Patent:
March 8, 2011
Assignee:
Coda Therapeutics, Inc.
Inventors:
Richard Colin Green, David Laurence Becker
Abstract: Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
March 1, 2011
Assignees:
E. I. du Pont de Nemours and Company, Pioneer Hi-Bred International
Inventors:
Anthony J. Kinney, Kimberly F. Glassman, William James Gordon-Kamm, Keith S. Lowe, Scott E. Nichols, Kevin L. Stecca
Abstract: This invention relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of telomerase genes, such as telomerase template RNA (TERC/TR), or a telomerase protein (TERT).